Evidence map›Paper›PMID 39258252›Full record

ArticleFrontiers in cellular and infection microbiology2024

Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in

Wenqi Zheng, Shitong Cheng, Fei Liu, Xinxin Yu, Yan Zhao, Fan Yang, Sataporn Thongpoon, Wanlapa Roobsoong, Jetsumon Sattabongkot, Enjie Luo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Evaluation of the transmission-blocking potential ofFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenqi Zheng *Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Shitong Cheng *National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China.
Fei Liu *Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Xinxin YuDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Yan ZhaoDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Fan YangDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Sataporn ThongpoonMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand.
Wanlapa RoobsoongMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand.
Enjie LuoDepartment of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
Liwang CuiDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Yaming CaoDepartment of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
Antigen discovery for transmission-blocking vaccines in Plasmodium vivaxR01AI150533 · NIAID · CHINA MEDICAL UNIVERSITY · PI CAO, YAMING · 2020 to 2024
$677k
NIAID NIH HHS R01 AI150533NIAID NIH HHS U19 AI089672
6 · The paper itself

Abstract

Background: Transmission-blocking vaccines (TBVs) can effectively prevent the community's spread of malaria by targeting the antigens of mosquito sexual stage parasites. At present, only a few candidate antigens have demonstrated transmission-blocking activity (TBA) potential in Methods and findings: The full-length recombinant PvQSOX protein (rPvQSOX) was expressed in the Conclusions: Our results suggest that PvQSOX could serve as a potential

Indexed as

Antibodies, ProtozoanMalaria VaccinesMalaria, VivaxPlasmodium bergheiPlasmodium vivaxRecombinant ProteinsAnimalsAntigens, ProtozoanEscherichia coliFemaleHumansImmunogenicity, VaccineMiceMice, Inbred BALB CProtozoan ProteinsRabbitsAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesProtozoan ProteinsRecombinant ProteinsDMFASPlasmodium vivaxquiescin sulfhydryl oxidasetransgenic parasitetransmission-blocking vaccine

Identifiers

PMID39258252
PMCPMC11385281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.